Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.49 |
| ▸ | ESRRB | O95718 | 1/20 | 0.49 |
| ▸ | ESRRA | P11474 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099341 | 0.85 | HSD17B10 (0.40) | ESR1ESR2ESRRBESRRATTR | |
| SCHEMBL30950666 | 0.80 | SMN1; SMN2 (0.43) | CNR1CNR2PIK3CDPARP1ALDH1A1 | |
| SCHEMBL6096600 | 0.80 | SMN1; SMN2 (0.43) | CNR1CNR2PIK3CDPARP1ALDH1A1 | |
| SCHEMBL30950664 | 0.77 | NT5E (0.49) | PIK3CDCYP3A4KDM4EALDH1A1ACHE | |
| SCHEMBL4297621 | 0.77 | NT5E (0.49) | PIK3CDCYP3A4KDM4EALDH1A1ACHE | |
| SCHEMBL2717940 | 0.77 | PIK3CD (0.40) | PIK3CDPARP1CYP11B1CYP11B2KDM4E | |
| SCHEMBL29665280 | 0.77 | NT5E (0.49) | PIK3CDCYP3A4KDM4EALDH1A1ACHE | |
| SCHEMBL11196149 | 0.74 | KDM4E (0.46) | ESR1ESR2ESRRBESRRATTR | |
| SCHEMBL9998065 | 0.73 | CNR1 (0.46) | CNR1PIK3CDKDM4EBACE1 | |
| SCHEMBL1663396 | 0.73 | CNR1 (0.43) | HSD17B10CNR1CNR2PIK3CDCYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303026-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2016-04-05 | — | — | US | disclosed |
| US-20140179709-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-06-26 | — | — | US | disclosed |
| US-8624025-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-01-07 | — | — | US | disclosed |
| US-20130005736-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-03 | — | — | US | disclosed |
| US-8217171-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2012-07-10 | — | — | US | disclosed |
| US-20110212966-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-09-01 | — | — | US | disclosed |
| US-7951955-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2011-05-31 | — | — | US | disclosed |
| EP-2314582-A1 | Heterocyclic compounds as antiviral agents | Biota Scientific Management Pty Ltd (AU) | 2011-04-27 | — | — | EP | disclosed |
| US-7829705-B2 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2010-11-09 | — | — | US | disclosed |
| US-7579465-B2 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGMENT PTY. LTD. (AU) | 2009-08-25 | — | — | US | disclosed |
| US-20090030000-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2009-01-29 | — | — | US | disclosed |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-7166604-B2 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-01-23 | — | — | US | disclosed |
| EP-1353911-A4 | ANTIVIRAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2005-01-05 | — | — | EP | disclosed |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2004-04-22 | — | — | US | disclosed |
| EP-1353911-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002050045-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | HAVCR2, EIF2AK2, MAVS | ESR1 4788/4885ESR2 4226/4885ESRRB 4312/4885 |
| US-20090030000-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ESR1 4794/4885ESR2 4498/4885ESRRB 4767/4885 |
| US-20130005736-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ESR1 4794/4885ESR2 4498/4885ESRRB 4767/4885 |
| US-20110212966-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ESR1 4794/4885ESR2 4498/4885ESRRB 4767/4885 |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | EIF2AK2, IFNAR1, HAVCR2 | ESR1 3778/4885ESR2 3767/4885ESRRB 4550/4885 |
| US-20140179709-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ESR1 4794/4885ESR2 4498/4885ESRRB 4767/4885 |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | RNASEH1, RPL35, SARS1 | ESR1 4737/4885ESR2 4450/4885ESRRB 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.